Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes

被引：13

作者：

Qian, Yimin ^{[1
]}

Corbett, Wendy L. ^{[1
]}

Berthel, Steven J. ^{[1
]}

Choi, Duk Soon ^{[2
]}

Dvorozniak, Mark T. ^{[3
]}

Geng, Wanping ^{[4
]}

Gillespie, Paul ^{[1
]}

Guertin, Kevin R. ^{[1
]}

Haynes, Nancy-Ellen ^{[1
]}

Kester, Robert F. ^{[1
]}

Mennona, Francis A. ^{[1
]}

Moore, David ^{[4
]}

Racha, Jagdish ^{[4
]}

Radinov, Roumen ^{[5
]}

Sarabu, Ramakanth ^{[1
]}

Scott, Nathan R. ^{[1
]}

Grimsby, Joseph ^{[3
]}

Mallalieu, Navita L. ^{[6
]}

机构：

[1] Hoffmann La Roche Inc, Dept Discovery Chem, Nutley, NJ 07110 USA

[2] Hoffmann La Roche Inc, Dept Pharmaceut & Analyt Res, Nutley, NJ 07110 USA

[3] Hoffmann La Roche Inc, Dept Metab & Vasc Dis, Nutley, NJ 07110 USA

[4] Hoffmann La Roche Inc, Dept Drug Metab & Pharmacokinet, Nutley, NJ 07110 USA

[5] Hoffmann La Roche Inc, Dept Proc Res, Nutley, NJ 07110 USA

[6] Hoffmann La Roche Inc, Dept Clin Pharmacol, Nutley, NJ 07110 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2013年 / 4卷 / 04期

关键词：

Glucokinase activator; type; 2; diabetes; lipophilic ligand efficiency; metabolite; redox cycling; BENZAMIDE DERIVATIVES; DISCOVERY; DESIGN; CANDIDATE; EFFICACY; THERAPY; SAFETY; POTENT;

D O I：

10.1021/ml400027y

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

To resolve the metabolite redox cycling associated with our earlier clinical compound 2, we carried out lead optimization of lead molecule 1. Compound 4 showed improved lipophilic ligand efficiency and demonstrated robust glucose lowering in diet-induced obese mice without a liability in predictive preclinical drug safety studies. Thus, it was selected as a clinical candidate and further studied in type 2 diabetic patients. Clinical data suggests no evidence of metabolite cycling, which is consistent with the preclinical profiling of metabolism.

引用

页码：414 / 418

页数：5

共 50 条

[31] Efficacy and safety of novel dual glucokinase activator dorzagliatin in type-2 diabetes A meta-analysis
Dutta, Deep
Khandelwal, Deepak
Kumar, Manoj
Sharma, Meha
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2023, 17 (01)
[32] Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat Type 2 diabetes: A review study
Jiang, Yu
Wang, Luyao
Dong, Zhenhua
Xia, Baotian
Pang, Shuguang
JOURNAL OF DIABETES, 2024, 16 (06)
[33] In the Clinic Type 2 Diabetes
Crawford, Allison L.
Laiteerapong, Neda
ANNALS OF INTERNAL MEDICINE, 2024, 177 (06) : ITC82
[34] Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus
Dzyurkevich, Mikhail S.
Babkov, Denis A.
Shtyrlin, Nikita V.
Mayka, Olga Yu.
Iksanova, Alfiya G.
Vassiliev, Pavel M.
Balakin, Konstantin V.
Spasov, Alexander A.
Tarasov, Vadim V.
Barreto, George
Shtyrlin, Yurii G.
Aliev, Gjumrakch
SCIENTIFIC REPORTS, 2017, 7
[35] Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus
Xu, Jiayi
Lin, Songnian
Myers, Robert W.
Addona, George
Berger, Joel P.
Campbell, Brian
Chen, Hsuan-Shen
Chen, Zhesheng
Eiermann, George J.
Elowe, Nadine H.
Farrer, Brian T.
Feng, Wen
Fu, Qinghong
Kats-Kagan, Roman
Kavana, Michael
Malkani, Sunita
McMasters, Daniel R.
Mitra, Kaushik
Pachanski, Michele J.
Tong, Xinchun
Trujillo, Maria E.
Xu, Libo
Zhang, Bei
Zhang, Fengqi
Zhang, Rui
Parmee, Emma R.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (09) : 2069 - 2073
[36] Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein
Slosberg, ED
Desai, UJ
Fanelli, B
Denny, IS
Connelly, S
Kaleko, M
Boettcher, BR
Caplan, SL
DIABETES, 2001, 50 (08) : 1813 - 1820
[37] Decreased expression of hepatic glucokinase in type 2 diabetes
Haeusler, Rebecca A.
Camastra, Stefania
Astiarraga, Brenno
Nannipieri, Monica
Anselmino, Marco
Ferrannini, Ele
MOLECULAR METABOLISM, 2015, 4 (03): : 222 - 226
[38] LINKAGE OF TYPE-2 DIABETES TO THE GLUCOKINASE GENE
HATTERSLEY, AT
TURNER, RC
PERMUTT, MA
PATEL, P
TANIZAWA, Y
CHIU, KC
ORAHILLY, S
WATKINS, PJ
WAINSCOAT, JS
LANCET, 1992, 339 (8805): : 1307 - 1310
[39] Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus
Mikhail S. Dzyurkevich
Denis A. Babkov
Nikita V. Shtyrlin
Olga Yu. Mayka
Alfiya G. Iksanova
Pavel M. Vassiliev
Konstantin V. Balakin
Alexander A. Spasov
Vadim V. Tarasov
George Barreto
Yurii G. Shtyrlin
Gjumrakch Aliev
Scientific Reports, 7
[40] MUTATIONS OF THE GLUCOKINASE GENE AND TYPE-2 DIABETES
HATTERSLEY, AT
TURNER, RC
QUARTERLY JOURNAL OF MEDICINE, 1993, 86 (04): : 227 - 232

← 1 2 3 4 5 →